SA
Go ProLog In
IBRX
OverviewIntelligenceChart
Q3 2026 EPS Estimate
$-0.09
Revenue Estimate
$49M
FY2028E EPS$0.48
FY2029E EPS$1.09

Analyst Sentiment

Wall St. Consensus
Buy
5 analysts·Limited coverage
75
Score
5 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
5100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$12.00
+49.1%
Consensus
$12.00
+49.1%
Bull
$15.00
+86.3%
12-Month Target Range5 analysts
$12.00$12.00$15.00
Current $8.05Consensus
Current Price
$8.05
Upside to Consensus
$3.95

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+137.42%
EPS—
FY2028
Rev+131.23%
EPS—
FY2029
Rev+85.29%
EPS+127.78%

Earnings Surprises

Recent Analyst Actions

May 8, 2026BTIG
ImmunityBio price target lowered to $12 from $13 at BTIG
Target:$12.00
+54.6%from $7.76
Mar 4, 2026Piper Sandler
Immunitybio Inc (IBRX) PT Raised to $12 at Piper Sandler
Target:$12.00
+30.4%from $9.20
Feb 23, 2026H.C. Wainwright
ImmunityBio price target raised to $15 from $10 at H.C. Wainwright
Target:$15.00
+54.6%from $9.71
Jan 20, 2026Piper Sandler
ImmunityBio price target raised to $7 from $5 at Piper Sandler
Target:$7.00
+26.8%from $5.52
Jan 10, 2025BTIG
ImmunityBio initiated with a Buy at BTIG
Target:$6.00
+147.9%from $2.42
Aug 3, 2022Jefferies
Jefferies starts ImmunityBio at Buy on Anktiva potential, IO pipeline
Target:$8.00
+93.9%from $4.13

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance